JP2023517532A - 粉末化された鼻腔内エピネフリンによる治療 - Google Patents

粉末化された鼻腔内エピネフリンによる治療 Download PDF

Info

Publication number
JP2023517532A
JP2023517532A JP2022552858A JP2022552858A JP2023517532A JP 2023517532 A JP2023517532 A JP 2023517532A JP 2022552858 A JP2022552858 A JP 2022552858A JP 2022552858 A JP2022552858 A JP 2022552858A JP 2023517532 A JP2023517532 A JP 2023517532A
Authority
JP
Japan
Prior art keywords
epinephrine
particles
pharmaceutical composition
type
dosage unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517532A5 (https=
Inventor
テムシン－クレイズ、ガリア
カジダン、パベル
Original Assignee
ナサス ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナサス ファーマ リミテッド filed Critical ナサス ファーマ リミテッド
Publication of JP2023517532A publication Critical patent/JP2023517532A/ja
Publication of JP2023517532A5 publication Critical patent/JP2023517532A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022552858A 2020-03-16 2021-03-16 粉末化された鼻腔内エピネフリンによる治療 Pending JP2023517532A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062989913P 2020-03-16 2020-03-16
US62/989,913 2020-03-16
US17/135,528 US11400045B2 (en) 2020-03-16 2020-12-28 Treatment with powdered intranasal epinephrine
US17/135,528 2020-12-28
PCT/IL2021/050288 WO2021186437A1 (en) 2020-03-16 2021-03-16 Treatment with powdered intranasal epinephrine

Publications (2)

Publication Number Publication Date
JP2023517532A true JP2023517532A (ja) 2023-04-26
JP2023517532A5 JP2023517532A5 (https=) 2024-03-27

Family

ID=77664091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552858A Pending JP2023517532A (ja) 2020-03-16 2021-03-16 粉末化された鼻腔内エピネフリンによる治療

Country Status (13)

Country Link
US (2) US11400045B2 (https=)
EP (1) EP4121005A1 (https=)
JP (1) JP2023517532A (https=)
KR (1) KR20220154709A (https=)
CN (1) CN115279340A (https=)
AR (1) AR121593A1 (https=)
AU (1) AU2021239084A1 (https=)
BR (1) BR112022018440A2 (https=)
CA (1) CA3175130A1 (https=)
IL (1) IL296268A (https=)
MX (1) MX2022011464A (https=)
TW (1) TW202200119A (https=)
WO (1) WO2021186437A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
KR20250048076A (ko) * 2022-08-11 2025-04-07 드 모투 코르디스 피티와이 엘티디 흡입형 에피네프린 제형
TW202502309A (zh) * 2023-05-31 2025-01-16 瑞典商奥瑞克索股份公司 包含腎上腺素激導性受體調節劑的噴霧乾燥之組合物
US20260108686A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531140A (ja) * 2013-09-03 2016-10-06 ジー２ビー ファーマ インコーポレーテッド 心肺機能蘇生（ｃｐｒ）、心臓の生命維持（ｃｌｓ）、アナフィラキシー及び／又はアナフィラクトイド反応の治療のための経鼻投与製剤
WO2019038756A1 (en) * 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
US20200069582A1 (en) 2014-07-03 2020-03-05 Darren Rubin Inhalable hemodynamic agents and methods of using the same
CN107205938A (zh) * 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
US11844859B2 (en) * 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
GB2600026B (en) * 2018-02-06 2022-10-12 Aegis Therapeutics Llc Intranasal epinephrine formulations and methods for the treatment of disease
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531140A (ja) * 2013-09-03 2016-10-06 ジー２ビー ファーマ インコーポレーテッド 心肺機能蘇生（ｃｐｒ）、心臓の生命維持（ｃｌｓ）、アナフィラキシー及び／又はアナフィラクトイド反応の治療のための経鼻投与製剤
WO2019038756A1 (en) * 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY

Also Published As

Publication number Publication date
CA3175130A1 (en) 2021-09-23
EP4121005A1 (en) 2023-01-25
TW202200119A (zh) 2022-01-01
WO2021186437A1 (en) 2021-09-23
KR20220154709A (ko) 2022-11-22
BR112022018440A2 (pt) 2022-11-01
MX2022011464A (es) 2022-11-14
US20210283050A1 (en) 2021-09-16
US11400045B2 (en) 2022-08-02
IL296268A (en) 2022-11-01
US20230105615A1 (en) 2023-04-06
AR121593A1 (es) 2022-06-22
CN115279340A (zh) 2022-11-01
AU2021239084A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
JP2023517532A (ja) 粉末化された鼻腔内エピネフリンによる治療
JP2020531417A (ja) 鼻腔内送達用乾燥粉末組成物
AU2021200503B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
CN105101955B (zh) 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物
AU2022395916A1 (en) Pharmaceutical device for use in intranasal administration
US20240358650A1 (en) Inhalable hormone receptor agonist formulations
US20250387327A1 (en) Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
MXPA05001901A (es) Composiciones para inhalacion con altas proporciones de medicamento.
TWI762449B (zh) 噴霧器用組成物
TWI597072B (zh) 包覆脂肪酸的β－致效劑之結晶微粒
HK40110667A (zh) 5-氨基-2，3-二氢-1，4-酞嗪二酮於治疗先天性肌肉营养不良症的应用
HK40090725A (zh) 糖皮质激素减量剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260128